China OKs Heterologous Booster Shots Amid Heated COVID Vaccine Race

Major Commercial Opportunity Opens Up

CanSino and Zhifei have received the regulatory green light for their respective COVID-19 booster shots in China and an estimated $1.3bn vaccine market is now up for grabs. Domestic contenders are set to elbow each other in the sector with a range of viral vector, recombinant protein and mRNA-based jabs.

mRNA COVID-19 vaccine
Estimated $1.3bn new market in China up for grabs by COVID-19 vaccine makers • Source: Alamy

Chinese regulators have removed the lid on an estimated CNY8bn ($1.3bn) domestic market to COVID-19 vaccine makers with the first approvals for heterologous booster jabs. Companies are now rushing to develop their candidates and inoculate potentially hundreds of millions of people.

Two producers, Shanghai- and Hong Kong-listed CanSino Biologics Inc. and Shenzhen-listed Chongqing Zhifei Biological Products Co. Ltd., obtained...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia